With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...